EOS 789
Alternative Names: AP-306 ; EOS-789Latest Information Update: 20 Dec 2023
At a glance
- Originator Chugai Pharmaceutical
- Developer Chugai Pharmaceutical; Shanghai Alebund Pharmaceuticals
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action Phosphate transport protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hyperphosphataemia
Most Recent Events
- 13 Dec 2023 Interim efficacy and adverse events data from phase II trial in Hyperphosphataemia released by Alebund Pharmaceuticals
- 14 Sep 2023 Alebund Pharmaceuticals completes a phase II trial in Hyperphosphataemia in China (PO) (NCT05764590)
- 27 Feb 2023 EOS 789 is still in phase-I development for Hyperphosphataemia (Combination therapy) in USA (PO)